Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

• Status: Active, not recruiting
• Trial end date: 2022-02-27
• Target enrollment: 0
• Participant gender: All

Summary

AntiCov-220 prevents and treats before, during, and after infection with SARS-Cov-2. The composition is fractionally extracted from herbs, using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cells protecting process, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Nguyen Thi Trieu, MD

Criteria

Inclusion Criteria:

• All patients with underlying medical conditions who have been taking medications for these conditions.

• Patients with AIDS, HIV, HBV, HCV, and patients with co-infections.

• The cancer patients are stable.

• Patients with congenital or acquired immunodeficiency.

Exclusion Criteria:

• Unstable cancer patients.